Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?
Could Help Patients Who Lack Own Antibody Response
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
You may also be interested in...
Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.
Coronavirus Update: Praised By Trump, Regeneron Files Antibody Cocktail For Emergency Use Authorization
Trump's praise of the therapy and talk of a 'cure' for COVID-19 has raised concerns about misinformation and pressure on the US FDA once again.
Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.